NCI-2022-05480

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

In this research study, they want to see if a new medicine called sacituzumab govitecan can help people with metastatic triple-negative breast cancer. Their cancer has either spread to other parts of the body, can't be removed with surgery, or has grown quite a bit but still hasn't spread all over. Pembrolizumab is a medicine that helps the immune system fight cancer, and it's meant to be helpful when the tumors have a protein called PD-L1. This protein can sometimes hide the cancer from the immune system. The goal of the study is to see which treatment works better for this type of breast cancer. The study will look at things like how much the cancer shrinks, how long patients live without their cancer getting worse, and how well the patients tolerate the treatments.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

​Triple Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05382286 NCI-2022-05480

Clinical Trial Site: Columbia

To see all available clinical trials click here.